- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01790802
Laser Intervention in Early Age-Related Macular Degeneration Study (LEAD)
A Multi-centre, Randomized Trial Into the Safety and Efficacy of Nanosecond Microsurgical Laser Intervention in Early Age-related Macular Degeneration
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
LEAD is a patient and assessor masked, multi-centre randomized controlled exploratory medical device clinical investigation of 240 participants (1:1 active to shame laser procedure) designed to assess the effectiveness of nanosecond laser treatment of patients with early high-risk AMD.
No less than 240 participants will be randomized into either active laser treatment or sham laser procedure groups at a ratio of 1:1. Patient eligibility based on ocular inclusion criteria will be evaluated using measures of vision, fundus photography, OCT imaging, and macular integrity (MAIA) performed during the qualifying period. Fundus images and MAIA results will be sent to a coordinating centre where these will be reviewed to confirm eligibility based on lesion attributes and the criteria specified in the protocol. Following confirmation of eligibility by the coordinating centre, participants whom satisfy all the inclusion and exclusion criteria can be randomized. Allocation to treatment group will be stratified by smoking status. All participants will receive either active laser treatment or sham laser procedure at the treatment visit and be assessed for retreatment on a semi-annual basis. All participants will be contacted by telephone at 1 week and present for clinical examination visits at 1, 6, 12, 18, 24, 30 and 36 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Centre for Eye Research Australia - Royal Victorian Eye & Ear Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females from 50 to 95 years of age at the time of consent
- Best corrected visual acuity (BCVA) of 6/12 (20/40) or better in each eye.
- Bilateral high-risk early AMD: At least one druse ≥125um within an inner macular zone (a circle with a radius of 1500 microns centred on the fovea) with or without pigment.
- A MAIA static threshold sensitivity less than 25 dB at any point, within a customized grid, as measured using a Macular Integrity Assessment (MAIA) device), at the same location of the one eye on two separate occasions.
- Pupil dilation of a least 5 mm in each eye
- Fundus photographs, optical coherence tomography (OCT) and fundus autofluorescence (FAF) images of adequate quality as assessed by the LEAD Image Reading Centre.
- Ability and willingness to consent, and be randomized, to the 2RT active or sham laser treatment, and all qualification and follow-up phases of the study.
Exclusion Criteria:
- Any evidence of definite geographic atrophy within the macula (a circle with a radius of 3000 microns centred on the fovea).
- Any black (hypofluorescent) area of FAF consistent with GA (roughly round or oval shape, sharp margins), and corroborated on colour photography as a patch of hypopigmentation.
- Any evidence of 'preclinical atrophy' as determined on OCT: loss of the outer retina (RPE and photoreceptors on the cube scan (Spectralis OCT) (49 horizontal B scans, 120 µm apart over a 20 x 20 degree scan). This covers approximately 6 x 6 mm in an emmetropic eye (N.B., peri-papillary atrophy (PPA) further than 1500 microns from the fovea is allowed).
- Current CNV, or past evidence of CNV in either eye.
- Any other experimental treatment for AMD, excluding dietary supplements, received in the past 12 months or thought likely to chronically change the course of the participant's retinal disease.
- Any OCT showing evidence of intraretinal fluid, or subretinal fluid for which CNV cannot be excluded as a cause.
- A subfoveal pigment epithelial detachment/drusenoid detachment greater than 1000 microns in diameter.
- Other macular disease with subretinal deposits not typical of AMD, e.g., Malattia Leventinese, Sorsby fundus dystrophy, Alports syndrome
- Ocular disease in either eye, other than AMD, which significantly compromises the ability to treat or visualize the fundus or would compromise the ability to assess any effect following laser application including;
- Known allergic hypersensitivity to fluorescein.
- Previous retinal or other ocular surgical procedures, the effects of which may now or in the future complicate assessment of the progression of AMD.
- Requirement for any systemic or ocular medication known to be toxic to the retina, such as: Deferoxamine, Chloroquine/Hydroxychloroquine (Plaquenil), Chlorpromazine, Phenothiazines, Ethambutol
- Any serious systemic disease that will preclude a 3 year survival and regular attendance for follow up.
- Sensitivity to contact lens application.
- Any condition that would make adherence to the examination schedule for 3 years difficult or unlikely.
- Any history of prior laser surgery to the retina.
- Intraocular pressures of 26mm Hg or higher or if there is some reason to believe the participant may have glaucoma
- Significant cataract: Nuclear cataract grade 2 or 3, cortical cataract Grade 2 or 3 or posterior subcapsular cataract Grade 2 or 3, by Simplified Cataract Grading System (WHO Cataract Grading Group).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active laser
Twelve 2RT nanosecond laser shots in two arcs of 6 shots superiorly and 6 shots inferiorly, inside the retinal vascular arcades at an approximate distance from the fovea of 3000 microns, with approximately one laser spot diameter between them.
|
active laser therapy
|
Sham Comparator: Sham laser procedure
The maximum illumination button on hte 2RT laser will be briefly pressed by the operating physician at each of the 12 locations where and when the laser would normally be applied.
The laser remains in standby mode preventing accidental laser firing.
|
active laser therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression to advanced Age-related Macular Degeneration (AMD) in the treated eye
Time Frame: 36 months
|
rate of progression to advanced AMD, either Choroidal Neovascularization (CNV), Geographic Atrophy (GA) or preclinical atrophy, in the study eye of treatment group compared to the sham procedure group
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression to advanced AMD in the untreated eye
Time Frame: 36 months
|
rate of progression to advanced AMD, CNV, GA or preclinical atrophy in the fellow (untreated) eye
|
36 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
reversal of early clinical indicators of AMD
Time Frame: 36 months
|
reversal of early clinical indicators of AMD (drusen area)
|
36 months
|
Improvements in visual acuity
Time Frame: 36 months
|
improvement in VA
|
36 months
|
Collaborators and Investigators
Investigators
- Study Chair: Robyn H Guymer, PhD, FRANZCO, Deputy Director CERA
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CERA201201
- ACTRN12612000704897 (Registry Identifier: ANZCTR)
- CTN Number130/2012 (Other Identifier: TGA)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age-related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Ocular Therapeutix, Inc.Duke University; FortreaRecruitingNeovascular Age-Related Macular DegenerationUnited States
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Ocular Therapeutix, Inc.CompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsWithdrawn
Clinical Trials on 2RT nanosecond laser
-
Nova Eye Medical Pty Ltd.Centre for Eye Research AustraliaRecruitingCentral Serous ChorioretinopathyAustralia
-
Center for Eye Research AustraliaAlphaRET Pty Ltd.RecruitingAge-Related Macular DegenerationAustralia
-
Cutera Inc.CompletedTattoo RemovalUnited States
-
First Affiliated Hospital of Zhejiang UniversityThe First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital... and other collaboratorsUnknown
-
Manchester University NHS Foundation TrustTopcon Corporation; Optos, PLCWithdrawnDiabetic Macular OedemaUnited Kingdom
-
University of Sao Paulo General HospitalCompletedOsteoarthritisBrazil
-
State University of Minas GeraisFundação de Amparo à Pesquisa do estado de Minas GeraisActive, not recruiting
-
Universidade Norte do ParanáUniversidade Estadual de LondrinaCompletedPerformance | Aged | Muscle Strength | Resistance Training | LasersBrazil
-
Mashhad University of Medical SciencesUnknownTemporomandibular Joint Disorder
-
Northwestern UniversityEnrolling by invitation